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Abstract
Background: Primaquine (PQ) is the only FDA-approved drug for radical cure of Plasmodium
vivax (P.v) malaria, but treatment can result in life-threatening hemolysis if given to a glucose-6phosphate dehydrogenase deficient (G6PDd) patient. Therefore, the G6PD status of the patient
with P.v must be known prior to prescribing PQ. However, patient G6PD status in rural malaria
endemic settings is generally unknown, illuminating the need for reliable point of care G6PD
diagnostic tests as a prerequisite to safely administer PQ. To increase community PQ access in
Cambodia, performance of CareStart™ G6PD rapid diagnostic tests (RDTs) needs to be
evaluated in healthcare workers (HCWs) and village malaria workers (VMWs).
Methods: Training materials on G6PD and PQ were developed for HCWs and VMWs and each
performed G6PD RDT test on 8-12 adult male volunteers, with pre- and post-training
questionnaires completed by trainees and G6PD test volunteers. The performance of CareStart™
RDT for G6PDd screening was assessed against a quantitative G6PD lab test (Pointe Scientific,
Inc. MI, USA). Descriptive and inferential statistics were used to analyze the data.
Results: 94 trainees and 960 G6PD volunteers were recruited in Oddar Meanchey province,
Cambodia from December 2017 to February 2018. Of the 960 volunteers, 156 (16%) were G6PD
deficient based on a quantitative test activity threshold of 30%. The sensitivity, specificity, PPV
and NPV of CareStart™ RDT were 96.8%, 95.5%, 80.2%, 99.4% for HCW/VMW trainees vs.
96.2%, 97.2%, 86.7%, and 99.3% for trained study staff in the field and 94.2%, 98.8%, 93.6%
and 98.92% for experienced laboratory staff, with no statistical difference among the groups. The
mean knowledge score pre-training was 33.9% (VMWs) and 56.4% (HCWs), with improvement
to 89% and 90% post training (p <0.001). Improvement in the HCW/VMW’s knowledge scores
was independent of years of experience, profession and education level. Perception of PQ risk
based on RDT results was assessed pre-and post-training.
Conclusions: With minimal training, CareStart™ RDT is highly specific, feasible and a practical
option for the identification of G6PDd male patients and its use may enable safer prescribing of
PQ to decrease the burden of P.v relapse.
Keywords: Malaria, G6PD, Primaquine, Rapid Diagnostic Test
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Background
Despite joint efforts by the national malaria control program and various international
partners working towards malaria elimination in Cambodia, these efforts continue to be a
challenge in this resource-limited setting. Progress has been hampered by antimalarial drug
resistance, and lack of access to curative doses of Primaquine for the treatment of Plasmodium
vivax. However, Primaquine (PQ) which is currently the only Food and Drug Administration
(FDA) approved drug that can eliminate hidden reservoir of P.v infections in the liver and
prevent frequent relapses, can also cause significant life threatening hemolysis if wrongly given
to a glucose-6-phosphate dehydrogenase (G6PD) deficient patient (Seidlein et al. 2013; RocaFeltrer A, Khim N et al. 2014).).
The World Health Organization (WHO) estimates that one million people are infected
annually with malaria (Population Reference Bureau, 2016). Among different malaria species in
Southeast Asia, Plasmodium vivax (P.v) accounts for 46% (26,183) of all malaria cases in
Cambodia (Sovannaroth, S et al. 2016). Cambodia’s National Malaria program (CNM) estimates
that the number of malaria outbreaks decreased. However, malaria remains as a major cause of
morbidity in Cambodia and requires a robust system and malaria management program to ensure
a successful elimination strategy (Population Reference Bureau, 2016).
G6PDd is one of the most common defective human enzymes affecting close to 400
million individuals worldwide. It is an X-linked genetic disorder that results in impaired enzyme
activity in erythrocytes (Gonzalo et al. 2013). G6PD enzyme protects erythrocytes against
oxidation by generating a reduced form of nicotinamide adenine dinucleotide phosphate
(NADPH). G6PDd a mutated G6PD gene, affects erythrocyte cell stability, especially when
exposed to 8-aminoquinoline drugs such as PQ required for cure of patients with P.v. Easy to
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use, reliable, and easily accessible screening for G6PDd is needed before PQ can be administered
safely (Amoah et al. 2016; Sovannaroth et al. 2016).
At the moment, the Cambodian National Strategic Plan for Elimination of Malaria
(CNM, 2011-2015) has procedures and strategies in place for training providers in the diagnosis
and treatment of malaria, but not for G6PDd screening, or the use of G6PD rapid diagnostic tests
(RDTs) at the community level (CNM, 2011). Despite reports of decreasing Plasmodium
falciparum (Pf) malaria in Cambodia, P.v elimination poses continued challenges, and the
country’s economic status is not well equipped to handle the needed costs for implementing
needed strategies and carrying out sustainable practices to ensure P.v elimination by 2025, the
goal set by the Cambodian government and WHO (WHO, 2015). Inexpensive G6PD screening
tests could increase access to radical curative doses of PQ but their reliability needs to be
assessed in the field settings to ensure safe deployment at appropriate level of care.
Demographics of the country
Cambodia is located in Southeast Asia, covering an area of 181,040 sq. km, and shares
borders with Vietnam, Laos and Thailand. Current population is 15,840,251. It has 25 provinces
and 13,406 villages (WHO, 2003; CNM, 2011). Public health centers provide basic medical care
for a small charge, such as $0.12 per visit for the out-patient department and a $5 charge for inpatient care (Chu et al. 2017). Neither private nor government health insurance is generally
available, particularly in rural areas (Sovannaroth et al. 2016) (Appendix A).
Geographical distribution
Currently, malaria elimination is a national priority with goals of eliminating P.f by 2020
and P.v malaria by 2025 (Canavati et al. 2013). The prevalence of G6PDd in Cambodia has been
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reported to be between 13-26% in males and 3-4% in females (Khim et al. 2013; Sovannaroth et
al. 2016).
Problem Statement
G6PD status of P.v patients must be known prior to prescribing PQ treatment in order to
avoid potentially life-threatening hemolysis from standard doses of PQ. The safe treatment for
P.v malaria depends on the reliability of results for G6PD screening, yet available screening tests
have not been evaluated in the field settings (Jalloh et al. 2004). In addition, the number of
studies evaluating the performance of G6PD RDT in Cambodia are relatively few, and prior kits
were only formatted for laboratory and temperature controlled settings (USAID, 2012). The
national malaria treatment guidelines for Cambodia recommended treatment of P.v patients with
PQ since 2012, with precise guidelines updated in 2014 (Sovannaroth et al. 2016). Despite these
recommendations, PQ is still not widely used in Cambodia due to the unavailability of reliable
G6PD diagnostic-field tests, unavailability of PQ, and insufficient data on how to train staff to
perform G6PD RDT tests safely.
Recent published data suggested that a new 3rd generation CareStart™ RDT may be more
suitable for field-testing, which might allow treatment implementation with PQ in patients with
P.v malaria (Roca-Feltrer, A. et al, 2014). However, to date, most testing of CareStart™ have
only been done in the laboratory settings by trained laboratory staff or by research investigators
(Gonzalo et al. 2013). In addition, the level of training that is required for novice users of G6PD
testing kits has not been established.
Purpose
The purpose of the study was to assess the performance of the CareStart™ in the hands of
HCW/VMWs in the field settings and compare it with the results from trained study staff
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(expert/observers) in the field and lab RDT, vs. the quantitative reference test (Ponte Scientific,
Inc. MI, USA). To achieve this, training materials were developed to teach HCWs, VMWs, and
lab technicians on how to reliably screen patients for G6PD using the CareStart™, and provide
standardized counseling to patients based on their G6PD results. The study also intended to
evaluate HCW/VMWs based on their ability to correctly perform and interpret the G6PD RDT
results, as well as their effectiveness in counseling G6PD test volunteers.
Specific Aims


Develop training materials to improve knowledge and acceptability of PQ use in G6PD
normal patients and assess the performance of the CareStart™ for G6PDd screening in
the field settings in the hands of HCWs and VMWs.



Compare the performance of CareStart™ for G6PDd screening in the field setting in
the hands of the HCW/VMWs vs. trained study staffs (expert observers) in both field and
laboratory settings.



Develop PQ treatment related counseling materials to educate patients regarding risks
and benefits of PQ in malaria case management.



Assess HCW/VMW’s knowledge of PQ, and their acceptability to assess the G6PD status
of malaria patients seen at their health centers, and willingness to prescribe PQ.
Research Questions

Among HCW and VMW with varied levels of education:


Does standardized training and education on the safe use and deployment of CareStart™
for G6PD screening result in comparable rates of correctly tested and interpreted RDTs,
and improve their knowledge?



How do the field RDT results compare with the results obtained in controlled settings in
the laboratory and against the gold standard quantitative testing?



Does education and training improve the willingness of HCWs/VMWs to give PQ post
training?
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Does education and training improve acceptability levels of malaria workers to test for
G6PD among malaria patients

Significance
PQ is the only FDA-approved drug that can provide radical cure from P.v. However, to
receive PQ, patients must be G6PD normal to prevent drug-induced hemolysis. Due to the
limited availability of diagnostic testing for G6PD in Cambodia, most patients only receive
treatment that eliminates malaria from the blood, without killing the liver stage parasites
(hypnozoites) (Khim et al. 2013). There is insufficient data in regards to modified PQ dosing
regimens for G6PDd patients in Cambodia that would make PQ safe for use in a wider scale.
Therefore, in order to use PQ in Cambodia, patients must be screened for G6PDd, and the
performance of these tests must be evaluated in the field and at the level of HCW/VMW
responsible for treating patients with malaria, before deploying PQ at these lower levels of care.
There is therefore an urgent need to identify G6PD screening tests that can be deployed
at the point of care, often at the village level, where patients with malaria seek care. Although a
field study assessing the performance of the available CareStart™ G6PD rapid diagnostic test
(RDT) was conducted in Cambodia in 2012, this was done in controlled laboratory setting, and
therefore uncertainty remains on how well CareStartTM RDT will perform when deployed in ‘real
world’ setting (Roca-Feltrer A, Kim S et al. 2014, 2012). The level of training and supportive
supervision required to effectively train village malaria workers (VMWs) and health center staff
on the correct use and interpretation of the RDTs have also not been fully assessed. Neither has
the acceptability among HCW/VMWs to incorporate G6PD test at the community level and their
acceptability to prescribe and give PQ given its potential risks. In addition, since G6PD
deficiency is bimodal with most G6PD deficient males having G6PD activity levels of <30%,
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WHO recommends that appropriate G6PD point of care tests should be able to detect all G6PD
deficient males with <30% activity. There is insufficient data if this can be achieved with
CareStart™ in the field settings, despite the promising results from the laboratory settings. Given
the potential risks associated with incorrect diagnosis of G6PD status, it is possible that use of
G6PD RDTs in a community setting might not be appropriate, but additional data is needed.
The WHO and National Center for Parasitology, Entomology and Malaria Control
(CNM) cautioned that the deployment of RDTs for G6PD should be piloted to evaluate RDT
performance in real-life field settings, which will ensure safe generalization of the program to the
Cambodian public. In addition, WHO (2015) stated that there is a need to evaluate feasibility,
effectiveness and acceptability of CareStart use at the HCW and VMW implementation levels in
the field settings, to address the knowledge gap.
Literature Review
Scopus, PubMed and Web of Science were searched for peer-reviewed studies published
between 2001-2017 in the English language using the key terms “malaria or P. vivax”, “G6PD
deficiency”, “RDT testing”, “CareStart RDT G6PD testing”, Point-of–care systems”, “healthcare
worker or malaria village worker training”, “Primaquine”, “PQ”, “Cambodia”, “malaria
elimination”. Studies were selected if they addressed or evaluated healthcare provider training
and G6PD RDT testing to assess for G6PDd. A total of 48 articles met search criteria.
Von Fricken et al. (2014) conducted a study to test the sensitivity, specificity, positive
predictive value (PPV), and negative predicative value (NPV) of 2nd generation CareStart™ in
the Haitian community. They screened a total of 456 participants, 267 females and 189 males all
healthy subjects. The kit generated sensitivity of 90% and NPV of 98.2%. This study concluded
that the 2nd generation testing kit was highly specific and effective at determining those with
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normal G6PD enzymatic activity in controlled temperature settings. However, the study only
used venipuncture blood samples, not finger prick samples, and only reported the results on a
very small number of deficient samples.
Another qualitative study was done by Roca-Feltrer et al. (2014) using (FST) fluorescent
Spot test. The study discovered that G6PDd prevalence rates and enzyme activity in malaria
patients are consistent with those in healthy individuals. This is important as these findings
suggest that testing for deficiency can be done at the time of acute malaria or before the
diagnosis of malaria is made. In addition, Khim et al. found that 2nd generation CareStart™
reliably detected deficiencies if the enzymatic activity was less than 30%. The results yielded a
sensitivity of 84.8%, specificity 93.7%, NPV 98.2% and PPV 60% noting that “the low PPVs…
were affected by the relatively low prevalence of severe G6PDd … in the sample population and
should not represent an impediment to the use of this RDT” (Von Fricken et al. 2014). Despite
the authors not stating temperature settings of this study, they recommended that HCW and
VMW should be equipped with tools to test for G6PDd. Both Khim et al and Brenden & Jitthai
(2012) agreed that the potential cost of RDT implementation into malaria management might be
a deterrent to meeting this goal. None of these tests evaluated the performance of CareStart at the
proposed end user level.
Cost
Kyaw et al. (2016) discussed the importance of cost analysis during a pilot study in
Myanmar to assess sustainability of the program. The authors concluded that annual cost of
supporting similar studies though sustainable in comparison with previous testing kits are
affected by the design of study, location (remoteness) and the ability to carry out surveillance
activity. In their study, up to 60% of the study finances were allocated to the supervisory work.
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Brenden and Jitthai (2012) also conducted a study on Evaluation of Malaria control in
Cambodia. The study assessed the cost of point of care (field) testing, and suggested that cost
should be leveraged based on provinces and not calculated for the whole country as this might
increase the overall cost. The authors suggested that the sustainability of VMW should be
assessed before training to ensure there is longevity of benefit to the healthcare facilities for
those trained. Kyaw et al. (2016) explained that despite the seemingly minimal cost of
CareStart™ kit and cost of treatment, (US$ 0.3 per RDT performed and US $0.5 per treated
patient) this cost is still not easily attainable for low income earners who make an average of $30
(thirty) dollars to $140 per month (Kyaw et al; Carmichael, 2015).
CareStart™ RDTs
Kim et al’s conducted a study in Pailin, west Cambodia using CareStart™ 2nd generation.
The test was carried out in a temperature-controlled research setting. At the time, CareStart™
falsely identified thirty-one (31) patients as “normal” when the subjects were G6PD deficient
based on the quantitative test done. The sensitivity and specificity was 68% and 100%
respectively. In 2012, the 3rd generation of CareStart™ was tested against the lab controlled
gold standard (quantitative test), and it showed sensitivity of 100% and specificity at 97.7%
compared to the quantitative assay among people presenting with G6PDd and <3.6 U/g Hg
enzymatic activity (Roca-Feltrer et al. 2014). Based on the results of this study and other
literature reviews, CNM made plans to deploy this 3rd generation RDT. Therefore, this study
will help CNM implement 3rd generation CareStart™ if the results of this study can be replicated
in the field setting, in the hands of the HCW/VMWs. Roca et al. previously noted that the
reliability of CareStart can be compromised if done outside of the manufacturers’ specified
temperatures of 18 °C to 32 °C (64.4°F- 89.6°F).
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G6PD Testing
G6PDd is widespread across malaria endemic areas like Cambodia (up to 26%). WHO;
Roca-Feltrer et al. 2014; Harvey and Bell, 2008; and Kim et al. (2011) all emphasized the
importance of screening for G6PDd in Cambodia. The authors stressed the importance of
ensuring feasibility and establishing appropriate endpoints for evaluating interventions. RocaFeltrer et al’s study included 938 adults with variable G6PDd levels, from moderate to severe.
The authors concluded that the newer, more user friendly tests (3rd generation CareStart™ ) can
effectively identify G6PDd subjects and aid in the efforts of eradicating P.v as it allows treatment
for majority of patients with P.v malaria, thus lowering P.v re-infection rates in the country.
In addition, Khim et al. enrolled 2,408 patients mainly from W. Cambodia in a bid to
study their G6PD status. Selected mean age was 26.7 years (range 2–81), ratio of males to
females was 3.9:1, of which 40.1% had P.v. The mean G6PD activity was 11.6, with close to
14% being G6PDd (335/2,408). This study concluded that deploying PQ in Cambodia should be
preceded by PQ safety studies paralleled with evaluations of easy-to-use tests to detect G6PDd
(Khim et al. 2013).
Theerathananon, Francois, Zongram & Kanchanakhan (2016) also surveyed 102 subjects
for G6PDd screening and assessed various variables including “demographic data, current
illness, malaria knowledge, malaria infection history, symptom, medication and prevention by
using questionnaire and in-person interview”. This study concurred with Khim et al’s claim that
men are 20% more likely to be G6PDd as opposed to females (13%). The study also indicated no
statistical difference in malarial infection between patients with normal G6PD versus those who
are G6PDd.
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Health worker Training (Appendix B)
Seidlein et al. (2013) assessed educational barriers and efficiency in RDT testing as this is
crucial for P.v elimination. The study showed that the performance of RDTs for G6PDd
screening has improved over the years. After training some malaria workers in Cambodia,
USAID (2010) concluded that approaching healthcare trainers as future trainers, and instructing
them as potential educators yielded the most participation and scored higher post-training in
teach-back. USAID noted that engaging the private sector when projects target low-income areas
caused a higher turn-out from local healthcare staff and patients. Greater sustainable results were
also achieved when healthcare trainees were encouraged to give feedback. As part of their input
to healthcare training, the President’s Malaria Initiative (PMI) developed several objectives for
Cambodia to be met by 2015, a process that is still pending. Some of these objectives include
advising the national malaria program on how to “perform risk-benefit analysis to inform
decision-making on administering or withholding radical cure when a patient’s G6PD status is
unknown, … testing for and interpreting G6PD tests and managing risk of hemolysis when PQ is
administered when G6PD status in not known” (WHO, 2015). Therefore, PMI supports training
of HCW and VMW to carry out the said objectives with the hope of making G6PD RDT testing
standard practice for malaria diagnosis and treatment (PMI, 2016).
Theoretical foundation for the development of study
The behavioral change communication (BCC) framework is a methodology that
emphasizes the use of dialogue and attempts to explain and predict health behaviors by focusing
on the attitudes and beliefs of individuals. To effectively implement the objectives of this study,
both BCC and Roll Back Malaria (RBM) initiatives should be engaged (RBM, 2012).
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Roll Back Malaria (2012) objectives employ the concepts of BCC methodologies that
emphasize the use of dialogue and participation. RBM “uses communication as an overarching
term to describe a planned process for influencing actions or responses among specific groups of
people” to enhance program effectiveness (RBM, 2012). One of the ways RBM will be utilized
is by increasing the health care provider’s’ knowledge on malaria, G6PDd, risks and benefits of
PQ treatment, and how to use RDTs for G6PD screening through standardized teaching materials
and hands on training (Acosta et al. 2014) (Appendix C).
Behavioral Change Communication (BCC)
The success of BCC goals relies on effective coordination and organization. BCC
theoretical framework is useful in bridging the gaps between successfully P.v eradication and
elimination through the training of both HCW and VMW. BCC promotes individual behavior
change, supportive environments… [and is a] key component of many malaria programs (Acosta
et al. 2014). BCC is also a collaborative process that helps create a bridge in communicating with
the communities. These steps in communication promote positive behaviors and are conducive
for positive outcomes. However, some authors are conflicted by studies that have incorporated
BCC, as these studies showed inadequate proof in regards to the benefits of BCC. However,
Acosta et al. claim that BCC is more beneficial when incorporated with malaria eradication
frameworks such as Roll Back Malaria. In the context of BCC, the success of this project relies
on the program organizers directly engaging the community and having the HCW/VMW lead in
the activities and distribution of educational materials. The benefit of this process relies on the
trust and communal bond that already exists between the villagers and malaria workers. As an
additional level of complexity, it was unknown at the time what role VMW can play in G6PD
screening, and if they can grasp the deployment of RDTs for G6PD without compromise of test
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results and thus affecting participant’s safety. Hopefully, communication and engaging
community involvement might help when the pilot study is implemented (Appendix D).
Identifying Variables
Assessing the strategies that contribute to malaria elimination and improving clinician’s
adherence to standards of practice based on national guidelines is vital for the project’s success.
Some of the variables included were demographic data, knowledge on G6PD and PQ, malaria
infection history, medication prescribing practices, and effectiveness of education using
questionnaire and teach-back (Appendix E); (Figure I).
Methods
Design
Quasi-experimental study was conducted in the P.v prevalent villages of west Cambodia,
where deployment of PQ is planned by CNM. Two primary reasons for choosing this design are:
1) it was a good fit to answer the proposed research questions; and 2) it was realistic and
feasible. The study assessed the feasibility and performance of VMWs and HCWs in using and
interpreting the 3rd generation CareStart™ over an 8-week period. At the workshop, we assessed
HCW/VMWs’ hands-on-practice using CareStart G6PD RDT. The trainees were observed and
evaluated four to six times at the end of the 2-day training, with each G6PD test performed using
commercially available G6PD deficient and G6PD normal control samples. Post-training in the
field setting, each trainee tested 8-12 G6PD volunteers. VMWs and HCW completed a survey
(questionnaire) on day 1, Day 2 and at the end of each G6PD testing day to assess their ability to
retain the knowledge they received during training, explore their willingness to use CareStart™
RDT and make PQ treatment decisions based on the RDT results.
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Study Sites and Population
This study was conducted in West Cambodia whose ethnic composition is primarily Khmer.
The location is relatively poor, agrarian (rice, rubber, corn, vegetables, cashews, tapioca), with
almost 75% being farmers and loggers. Cambodians average annual income is approximately
3,735 USD. Most of the people living in this area have either a primary and secondary level of
education (Grade 1-6 and Grade 7-9), and statistics show that 100% of individuals aged 15 or older
can read and write. (CIA, 2008).
The target population: The study population consisted of two groups: (1) VMWs, HCWs
(nurses, laboratory technicians) and (2) G6PD blood donor (G6PD test) volunteers who reside
in these malaria endemic villages of west Cambodia.
Sampling Plan
The study utilized convenience sampling method.
Inclusion criteria:


HCWs/VMWs working in Cambodia, Oddar Meanchey Province (Anlong Veng and
Trapang)



Healthy male volunteers at least 18 years old. Only male test volunteers were screened,
since females can have 2 populations of red blood cells simultaneously, G6PD normal
and G6PDd, and the distribution of G6PDd and G6PD normal red blood cells (RBCs) is
determined at random. CareStart™ kit cannot identify “intermediate” females, who have
a mix of normal and deficient cells. RBCs with G6PD normal activity produces G6PD
normal result, however following PQ administration, the fraction of G6PDd RBCs are
subject to drug-induced hemolysis, which can result in a drop in hemoglobin level
(Thriemer et al. 2017; Malar J. 2017). Presently, only quantitative tests can provide
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results on the actual G6PD levels and thus reliably identify those females who are G6PDd
with activity of 30 - 70% (WHO, 2004).
Exclusion criteria:


HCWs or VMWs not able to understand spoken and written Khmer



Patients with severe illness requiring immediate hospitalization and treatment



HCWs/VMWs not able to stay for the duration of the study

Sample size
Formal sample size calculations are not required for feasibility studies. However, to
calculate the ideal sample size, assuming a small effect size (Cohen’s d of 0.30) (we did not expect
to see greater difference in knowledge score or ability to correctly test and interpret CareStart
G6PD RDT results between HCWs/VMW and expert reading as per Khim et al. 2013), the power
of 80%, with alpha of 0.05, the study would require G6PD test volunteer sample size of 139. For
this study, up to 150 health-worker trainees were recruited and104 enrolled.
However, previous studies conducted in Cambodia reported G6PD prevalence in males of
15%. The sensitivity of G6PD RDT tests to detect G6PDd (<30% enzyme activity) in ideal lab
conditions was expected to be 99 to 100% based on Roca-Feltrer (2014). Therefore, to detect a
difference in the test sensitivity from 99% (ideal) to 95% (trainees), it required a sample size of
1560 (80% power using 5% two-sided test) and 15% prevalence of G6PDd. In this population of
15% G6PDd, to detect 4% difference in the prevalence of G6PDd (15% vs. 11%), when the test is
conducted by expert readers (trained study staff) vs. trainees, the minimum sample is 1274
volunteers (80% power, 5% two-sided test).
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Setting
West Cambodia, border of Thailand, a malaria-high zone area. The targeted healthcare
facilities and village areas have approximately 800-1000 patients seen at these facilities on a
monthly basis. Participants were enrolled from the district referral hospital, approximately 11
health centers, 1 Health Post and multiple VMW posts at or near Anlong Veng and Trapang Prasath
district, Oddar Meanchay Province in Cambodia. The healthcare facilities have 33 HCW and the
province has 174 VMW (covering 50 villages).
Study duration
The entire study was planned to be carried out over a 12-month period to allow for
development of training manuals, Data Collection Forms, consent forms, survey forms and
training of malaria workers; however, individual participation of HCW/VMW lasted no more
than 3 months for trainees, and one day for G6PD test volunteers (Table A).
Recruitment of participants
The Armed Forces Research Institute of Medical Sciences (AFRIMS) team in Cambodia
advertised the screening on public notice boards with the authorization of the village chiefs.
Meetings were held with the ministry of health and Malaria Elimination program representatives.
G6PD test volunteers were screened, consented and enrolled by AFRIMS study team. Patients
seen at the health centre who met the inclusion criteria were recruited as G6PD test volunteers by
study team and trainees. Trainees were recruited from there working stations (VMW locations
and healthcare centres). Each trainee was required to obtain a signed supervisors note to enrol in
the study (Appendix I; Appendix F).
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Informed consent Process
Written Informed Consent form (ICF) was obtained from HCW/VMWs and every G6PD
test volunteer prior to study participation. The completed ICFs were retained by the investigators
as part of the study records and a copy was provided to each study volunteer. All ICFs were
translated into the local language (Khmer). For the illiterate volunteers, the consent form was read
to them in Khmer in the presence of a witness who then signed and dated the consent form in the
presence of the participant. The participant then thump printed the ICF in the allocated line
(Appendix G).
Intervention
The study was carried out in 2 phases. During Phase 1: training materials were developed
and training provided to the HCWS/VMWs using the tools developed. All trainees had to pass
the knowledge test (Appendix H). In Phase 2: the trainees screened G6PD volunteers using
CareStart™ RDT. All trainees had to correctly read and interpret the results for each test done.
Instrument and Measurement
A Power-Point training manual on G6PD and PQ (dose, risks and benefits) was developed
for use at the workshop together with a standardized questionnaire to help assess knowledge,
acceptability and perceptions of the trainees in regards to PQ use and CareStart RDT. AFRIMS
professional medical linguists translated all questionnaires from English to Khmer. The
translations were authenticated and certified. The questionnaires had both structured and semistructured questions, using 7-point Likert scale with varying responses such as not willing to
willing or not comfortable to comfortable on a scale of 0 to 7. The demographics gathered
included participants age, occupation, gender, current residence, and level of education
(Appendix J).
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How to scale and score G6PD RDT
Field-tested G6PD status was based on a-Yes or a-No result depending on color change
(Yes/deficient: white color, or No/normal: purple color (Appendix: Figure 2). However,
quantitative test was used as a reference to classify volunteers as having a normal or deficient
G6PD status based on the lab values (Appendix J).
1) Performance was assessed by:
i) % of tests interpreted correctly by HCWs/VMWs (RDT colour result meaning deficient
or normal)
ii) % of CareStart™ correctly interpreted (against trained study staff and quantitative test)
2) Feasibility of G6PD RDT use by HCW/VMWs and assess their response to administer
hypothetical PQ by:
a. % of HCW/VMWs stating they would be willing to prescribe/ or give PQ based
on the RDT result and based on the counselling information provided (Not willing
=1, willing = 7). The respondents were also given the option to comment if they
answered “If yes” …, how likely) (Appendix J).
3) Acceptability to testing for G6PD and willingness to give PQ questionnaires were based on a
7-point Likert scale. The questionnaires consisted of a total of 10 Likert- scale questions. The
scales assessed:
a) % of HCW/VMWs willing to use G6PD RDT as a routine component of malaria case
management. Also measured by responding (Not-comfortable =1 to Comfortable =7 with
using RDTs).
The questionnaires consisted of 25 structured questions that assessed trainee knowledge on
G6PD, CareStart™ and PQ. Each correct answer received one score. The HCW/VMW pre-training
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questions were a total of 44 questions and Post-training questions were a total of 42 questions,
excluding demographics.
Training and testing for G6PD
HCW/VMWs. A 2-day training was held in Khmer language using “Teaching Manual
PowerPoint” that was developed for this project. The class consisted of 104 trainees
(HCW/VMWs), but only 94 completed the study. The first day consisted of theoretical training
that covered the topics on G6PD deficiency, CareStartTM G6PD RDT, PQ associated risks and
benefits, and how to recognize side effect. The teaching manual also covered the current treatment
guidelines for malaria in the country. PQ Counseling script (Appendix M) was reviewed with the
trainees to aid them in effective counseling of G6PD test volunteers.
Following the theoretical training, a practical hands-on workshop was conducted using
CareStart G6PD RDT on 2nd day of workshop (Appendix N). To accurately evaluate the results,
control samples of known G6PD activity (normal and deficient samples) were purchased from
ACCESSBIO (the maker of CareStart™) for use during the hands-on training sessions. The
overall goal of the 2- day training and subsequent follow-up was to ensure HCW/VMWs could
reliably screen the volunteers and effectively counsel them based on their G6PD results, and
make hypothetical treatment recommendations based on the national treatment guidelines
(Appendix O).
After the 2-days of training, each HCW/VMW was assigned a total of 16 G6PD files
to use in field. Each trainee was assigned an expert observer (who is trained study staff) to evaluate
their procedures in the field setting. A Checklist was used to ensure that accurate steps were carried
out, plus accurate recording of results; and that questions regarding hypothetical dosing of PQ
were answered. CareStart performance was assessed in the hands of HCWs/VMWs, and results
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compared against the expert readers(observers) in the field vs expert in lab using RDT, then all the
three tests were compared against the quantitative lab test (Pointe Scientific, Inc.) which is the
current gold standard “quantitative” method of G6PD screening in the laboratory.
However, the volunteers were not informed of the G6PD RDT results even if the results
indicated deficiency until all the quantitative tests were done as a “gold standard” to confirm the
results. At the end of the study, every G6PD volunteer who had consented to knowing their
G6PD status was informed of their status by a designated study team member.
Trainees also answered a set of questions, using pre and post-training questionnaires. The
pre-training questionnaires consisted of 44 semi-structured questions but only 25 knowledge
questions were scored for knowledge assessment. The other questions were 7-point Likert scale
that assessed participant’s perception of their willingness to prescribe/give PQ or to test the
G6PD status of patients coming to the health centers with malaria. The post-training
questionnaire consisted of 42 questions; the same 25 knowledge questions were scored post
training to assess if HCW/VMWs retained the information given during training. This was
assessed at 2-days post training, and at two, four, six and eight weeks. The study staff probed
HCW/VMWs understanding of each major topic area covered on G6PD and PQ. A checklist was
used. Trainees who failed to receive 100% understanding on any given topic received additional
instruction on the specific topic missed. HCW/VMW underwent this process and repeat
counseling script training until they were able to mark “yes” to every queried section of the
counseling DCF (Appendix N).
Blinding
HCW/VMWs were blinded to the (expert’s) trained study staff’s G6PD test results until
both results were recorded and locked to avoid untoward bias. The Trained study staff performed
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the test first then observed HCW/VMWs do the test. However, both HCW/VMW and observer
were blinded to the quantitative results until RDT results were “locked” in the Data Collection
form.
Blood sample collection
Currently, CareStart™ is the only “field friendly” test available for field G6PD testing. It
is also less temperature sensitive than other qualitative G6PD tests. Enzyme activity is shown
through a visual dye colorization, (white = deficient; purple = normal), but is limited by the lack
of a built in control signal. The CareStart™ does not require refrigeration with recommended
storage temperature of 18-32°C.
Process of Sample Collection. The blood samples for G6PD RDT testing in the field was
collected via finger prick, the CBC and G6PD testing in the laboratory were performed on venous
blood samples. All sample collections were performed under sterile technique. For field test using
RDT kit, 2µl blood was pipetted from a finger prick, [ and from EDTA vacutainers in lab]. The
pipetted drop of blood was added to the sample well using the pipette provided. Then, two drops
of buffer supplied by the manufacturer was added to the buffer well. The results were then read in
10 minutes according to the manufacturer’s guidelines. HCW/VMWs carried out all the procedural
steps for testing for G6PDd, but the trained study staff performed blood test first, and
HCW/VMWs’ then performed second. In addition, a 2 ml venipuncture blood sample was obtained
from each ‘patient’ in Vacutainer tubes (BD Vacutainer, Franklin Lakes, NJ) containing EDTA
(K2 Ethylenediaminetetraacetic acid) as an anticoagulant, for CBC, lab RDT and quantitative
G6PD testing (Von Fricken et al. 2014; Gonzalo et al. 2013). RDTs from the same batch were
used for all participants. All field participants were blinded to the results from the
spectrophotometric analysis (quantitative test).
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Data Collection
Data collected were recorded in data collection forms (DCF) and transferred to the electronic
database, which was password protected. Demographic data was gathered using study developed
questionnaires. The study collected data consisted of:
a. Questionnaires to assess acceptability of PQ treatment and effectiveness of training,
completed by HCW and VMW; and willingness to test G6PD status of patients with
malaria, and knowledge assessment.
b. CareStart™ G6PD test results (RDT) from the field and quantitative lab results from a
reference laboratory (G6PD, CBC)
Validity and Reliability of Instrument
HCW/VMWs evaluation. Post training, each HCW/VMW performed four to six G6PD
RDTs using known control samples (deficient and normal). Trainees were observed by an expert
reader (trained study staff) during the workshop training held over a 2-day period. Subsequent to
workshop training, HCW and VMWs performed G6PD RDT test in the field setting where they
were also observed by trained study staff to ensure correct reading of results.
Reference Standard. The G6PD spectrophotometric quantitative analysis used Pointe
Scientific, Inc. (MI, USA) G6PD reagent kit. Samples collected were analysed within 24hours.
G6PD activity was calculated and reported using the international units, corrected for haemoglobin
levels (Appendix L).
Acceptability survey. At the end of each field day, to help explore trainee’ knowledge and
understanding of G6PD and PQ, HCW/VMW completed questionnaires regarding their
willingness to use the G6PD RDT routinely and acceptability to prescribe/give PQ, and also their
understanding of PQ risks (Appendix J).

23
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING
Data analysis
The analyzed data was retrieved from case report forms (CRF) developed for this study.
This raw data was then entered into the electronic database, and transcribed to excel spreadsheet
for analysis and reporting using STATA 15 program, SPSS and Graphpad Prism 7. p-values
<0.05 indicated statistically significant differences. Sensitivity, specificity, PPV and NPVs for
RDTs in the field and lab setting were calculated against the population adjusted median of 30%
on reference quantitative test. Descriptive and inferential statistics were also used to analyze data
collected. Data was downloaded directly into SPSS once it was recorded for final analysis. Test
performance at the field was compared between samples collected from the finger prick and from
venous samples analyzed in the lab.
The experts assessed trainees’ (HCW/VMW) level of understanding about G6PD RDTs
and PQ, which was indicated by the percentage of accurately performed and correctly interpreted
tests. Any missing data was assumed as failed result. Lost to follow-up was low based on single
visits required for the G6PD test volunteers and the trainees worked from their usual working
stations.
Data Dissemination. The results of this study will be presented to CNM and AFRIMS. In
addition, key findings will be presented to key country stakeholders, during AFRIMS sponsored
workshop.
Ethical Considerations
The study received approval by the National Ethics Committee for Health Research of the
Ministry of Health of Cambodia and WRAIR IRB. In addition, the protocol was submitted for
review by The George Washington University IRB (GW) to assure compliance with any GW
institutional policies. We submitted all amendments for review and approval by all institutional
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review boards. There were no unanticipated problems involving risks to volunteers or others, and
no significant deviations. Informed consent was obtained from the volunteers before inclusion in
the study and before any study procedures. The participants’ records were kept confidential with
limited access to records by study staff only. G6PD volunteer participants were informed of their
G6PD status based on agreeing to receive results signed on the consent form. Result received were
based on the gold-standard quantitative test results.
Results
From December 2017 to February 2018, 94 trainees completed the 2-day training
workshop, including 21HC staff and 68 VMWs. In this eight-week period, 960 adult male
volunteers were assessed for G6PD deficiency. The median age of the trainees was 37 years,
with a range of 18 to 69 years old (Appendix Q).
I.

Knowledge Assessment and Acceptability Survey
Trainee knowledge about G6PD and PQ was assessed based on their professional titles,

educational levels and years of experience at their current position. At baseline, nurses had the
highest knowledge score of 56%, but all the trainees showed improvement in their knowledge
scores from pre- to post- training, with statistical significance in results post training (p<0.001).
Table 1. Knowledge score: Pre and Post-training based on trainee background

Trainee profession
 VMWs (n=68)
 Nurses (n=21)
 Other HC workers (n=5)
TOTAL (t, p-value)
Trainee level of Education
 College graduates
 High school graduates
 Primary

Pre-Training %
mean score of
each profession

Post-Training
% mean score of
each profession

34%
56.4%
34%

88.71%
90.0%
96%

Statistics, p
value

t=16.6
p <0.001
53%
48.9
33%

95%
92.4
89.8%
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Secondary
TOTAL (t, p-value)

Years in Experience
< 1 year
1- < 3 years
3- < 5 years
>=5 years
Total (t, p-value)

38%

84.4%
t= 16.30, p
<0.001

% mean pretraining
38%
37.5%
41%
37.33%

% mean posttraining
91.33%
89.5%
78.67%
91. %2
t= 16.30, p<
0.001

Pre-training, knowledge scores based on education level indicated that college graduates
had the leading percentage mean score of 53% with primary-level educated volunteers scoring
33%. Post-training, college graduates had mean score of 95%, volunteers with secondary school
education scored at 84.4%, and primary level scoring 89.8%, which was not statistically
significant between the groups. VMWs with primary school level education, and 1 to 3 years of
experience, scored the highest (p=0.38). Post training, scores for willingness to test for G6PD
deficiency, and comfort in prescribing PQ for Pf and P.v significantly improved. In relation to
years of experience, there were no statistical differences in the mean knowledge scores based on
profession (p=0.57) and education level (p=0.38).
Table 2. Willingness to perform the test and level of comfort in giving treatments
Pre-Training

Post-Training

Willingness to test for G6PD when a patient is
diagnosed with malaria

56.3% (53/94)

80.8% (76/94)

Level of comfort in giving PQ based on G6PD RDT
results

39.3% (37/94)

72.3% (68/94)

Level of comfort in giving PQ to a patient with P.v
and normal G6PD test

36.1% (34/94)

80.0% (76/94)

Willingness to give a patient PQ single dose for P.f
without G6PD screening

20.2% (19/94)

84% (79/94)
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II.

CareStart G6PD RDT Results

Calculating the G6PDd <30% cut-off of adjusted male median: 1,127 adult males with
at least 18 years of age were included in analysis. The G6PD median value (IQR) was 8.30 (7.11,
9.61). Mean (SD) of G6PD activities was 7.72 ( 3.35 U/g Hb. Nineteen males who had
G6PD quantitative value equal or less than 10% (0.83 U/g Hb) were exclude in order to calculate
“adjusted G6PD male median value”. Adjusted G6PD male median value (IQR) was then
estimated from 1,108 volunteers was 8.35 (7.22, 9.655). G6PDd was defined as <30% of
adjusted male median value which is <2.51” U/g Hb. The distribution of G6PD enzymatic
activity of our sampling population according to lab spectrophotometry ranged from 0.05 to
22.57. Sensitivity was described as the probability that the RDT test classified an individual as
G6PDd, who is also classified as deficient by the quantitative assay; detecting <30% of
enzymatic activity (<2.51U/g). Specificity was described as RDT results concurring with lab
results as G6PD normal (>2.51U/g).
CareStart G6PD RDT Results. We used IBM SPSS to analyze G6PD RDT test results.
Of the 960 volunteers, 156 (16%, 95% CI 14-18) were G6PD deficient based on a quantitative
test activity threshold of 30%. The results of field-tested CareStart™ were compared with the
spectrophotometric methods in the laboratory at the threshold of 30% adjusted male median
activity. There was no statistical difference in test sensitivity, specificity, PPV and NPV for
CareStartTM at the field site (96.53%, 95.69%, 80.81%, 99.32%) compared to the results by the
expert in the same field conditions (95.86%, 97.40%, 87.42%, and 99.21%), and 93.79%,
98.96%, 94.44%, 98.83% for experienced laboratory study staff, with no statistical difference
among the groups. HCW/VMWs classified 35/960 (3.64%) volunteers incorrectly as being
G6PDd (when they were G6PD normal), compared to 20/960 (2.08%) expert in the field, and 8
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(0.8%) by the expert in the lab. HCW/VMWs missed to identify 5/960 G6PDd volunteers,
compared to 6/960 misclassifications by the experts in the field, and 9/960 by the expert in the
laboratory (Appendix P).
Discussion
This is the first study that has evaluated CareStartTM G6PD RDT test in the field settings
in Cambodia in the hands of village malaria workers and other health care workers, who were
mostly nurses working at health centers. This is also the first report of the established normal
G6PD activity levels based on Point Scientific Quantitative Test, which is currently the
recommended reference test following discontinuation of the Trinity kits from production. No
prior studies evaluated community perception on PQ, G6PD screening, and provider comfort
with prescribing PQ based on RDT results using CarestartTM, the only point-of-care testing
available. The training also allowed us to assess how the perceptions about PQ risk and
limitations of G6PD screening can change, which is important in rolling out radical cure
treatment for P.v in Cambodia.
The results of the study showed that trainees showed much higher willingness to screen
patients for G6PD deficiency following the 2-day workshop training likely due to increased
understanding of the benefits and risks of PQ. CareStart G6PD RDT offered at point-of-care
testing performed reasonably well even at the peripheral level of care, at the community level by
village malaria workers. Making this test available at this level could increase access to testing
and radical cure treatment. However, it remains to be seen if VMWs can be given this new
responsibility to screen patients for G6PD deficiency and prescribe PQ which is not without
risks. Based on our results, the tendency of trainees was to over diagnose G6PD deficiency,
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which explains the lower PPV. However, no group was free from missing the diagnosis of
G6PD deficiency.
The implication of this is important for the policy makers as PQ deployment will not be
without risks, even with G6PD screening. It is possible that new generation tests for G6PD
deficiency could become more reliable, but this is yet to be demonstrated in the field trials for the
next generation G6PD kits that are in development. CareStart RDT is currently the only point-ofcare test that is available commercially and that can provide an inexpensive way to test male
patients for G6PD deficiency with little time required to make trainees proficient in interpreting
the test results.
Kim et al. (2011) study indicated that CareStart had 90% sensitivity with a NPV of 98.2%
in the controlled laboratory settings. Our study showed higher sensitivity and better NPV of
99.29, likely reflective of the training provided, which was effective across all education levels
and years of experience. Given the acceptable level of performance in the field settings even
among novice users post training, it makes the results widely applicable for implementation in
this malaria endemic areas. Implementation of the CareStart kit may be feasible at the
community level, with limited training required and with added benefit of the low cost of
CareStart in comparison to the quantitative tests that can only be done in temperature controlled
laboratories.
Study Limitations
Wide applicability of our findings should be taken with caution when similar approaches
are considered for implementation in other countries. Some of the trainees had difficulty with
reading the digital clocks, which is required to indicate the reading of results at10 minutes mark.
This resulted in the switch from digital clocks to using timers, with audible sound at the 10 mins
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mark. The smaller size timers were difficult to set and were later replaced by another brand of
the timers. These details in implementation should not be overlooked.
In regards to pre- and post- training questionnaires, some HCWs/VMWs stated that it was
too long and therefore, took long to complete. They also stated that despite the fact that the
questionnaires were translated into the local language (Khmer), some of the questions were still
reported as “technical” and required explanation by the (experts)study staff, which could have
introduced some degree of bias in the results. The trainees also provided us with feedback that
the pictures in the counseling script were more helpful than reading of the script to the G6PD test
volunteers. Most trainees and G6PD test volunteers found the pictures and explanations of the
pictures sufficient for understanding the concepts, and a better method for them to learn as
opposed to reading the whole script. One limitation to using CareStart™ was lack of the control
line, which was previously recognized as a significant limitation from prior studies in the lab
setting. In this case, supervision of testing will be beneficial, possibly in the form of re-training
to make sure that trainees read the tests correctly, follow proper procedures, and record the
results within the specified time of 10 minutes; otherwise, delayed reading can result in wrongful
interpretation of the results.
Implications for practice, policy and research
The outcomes from this study show that with limited training, novice users can become
quite proficient at reading and interpreting CareStartTM RDT results. This test is only suitable for
use in male patients. However, with males being the predominant population affected by malaria
in Cambodia, deployment of this test can increase access to radical curative doses of PQ.
Increasing access to G6PD screening will allow more patients to be cured from P.v and this can
help with prompt implementation of malaria elimination goals that have been set to eliminate P.v
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in Cambodia by 2025 (MESA, 2016). The piloted G6PD counseling tools were highly effective
and could be modified and adopted for wider use in clinical practice in Cambodia.
Conclusions
CareStart RDT shows promising results in terms of test sensitivity and ruling out G6PD
deficiency. This study indicated that point-of-care screening for G6PD deficiency at the
community level is feasible. However, incorrect interpretation of a few G6PD RDT test results
will occur, and monitoring must be put in place before deployment of PQ treatment in
Cambodia. Willingness of patients to be treated with PQ despite risks will likely result in lower
cases of P.v malaria recurrence, and malaria morbidity from frequent P.v relapses in Cambodia.
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Appendix A: Current Map of Malarial Incidence in Cambodia
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Appendix B: Training Manual (English, also translated to Khmer).
PowerPoint Slide that covered several Objectives


Provided a rationale for recommending treatment with Primaquine



Educated on risks and benefits of Primaquine treatment following G6PD deficiency
screening



Reviewed recommendations on who needs G6PD screening



Provided training on the correct use and interpretation of RDTs for G6PD deficiency
screening



Provided an overview of the current limitations of available point-of-care testing for
G6PD deficiency



Trained healthcare workers using a formulated “Counseling Script” on Primaquine
and G6PD screening
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Appendix C: Communication planning model developed by NIH and CDC (RBM, 2012)
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Appendix D: Variable Table with Theoretical and Operational Definitions

Variable

Theoretical Definition

Gender
Age

Demographics
Patient’s biological sex
Chronological age in years

Race

Biological or genetic traits
based on various sets of
physical characteristics

Educational level

Level of educational level
completed

Primaquine 1

Primaquine 2

Perception of threat
Susceptibility to malaria
RDT G6PD test results

Effective counseling of PQ
safety

Dependent
Recommended as part of
treatment for P.vivax (radical
cure course)
Recommended as part of
treatment to block malaria
transmission (single dose)
Based on demographics and
recent history of malaria
Based on demographics and
recent history of malaria
Concordance of RDT results
by VMWs and trained study
staff
Effective communication on
PQ safety, as assessed by
volunteers level of
understanding of risks and
benefits

Operational Definition

1=Male 2=Female
Years of age as defined
as current date minus
birth date. Defined as:
1=18-<30, 2=30-<45,
3=45-<60, 4=>60
1=Caucasian
2=Black
3=Hispanic
4=Asian
5=other
1=Grade school
2=High school
3=College
4=Graduate school

Yes=1 No=2

Yes=1 No=2

Is patient G6PD deficient
Yes=1 No=2
Yes=1 No=2
Yes=1 No=2

1=Volunteers not able to
clearly state side effects
of PQ or signs or
symptoms of hemolysis
2=Volunteer able to cite
one symptom of
hemolysis but reports
lack of understanding
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Healthcare training

Effective teach-back

Level of education/literacy

Independent
Education level of trainee

Training module

Type of training received
and teach-back

Malaria P. vivax control
and prevention practices

Healthcare staff education
(nurses, medics, malaria
village workers) and patients
are counselled on malaria
management

RDT testing

G6PD screening with RDTs

when to seek medical
career
3=Volunteers reports
understanding of the side
effect profile of PQ, can
state when he/she needs
to seek medical care, and
can recite clearly most
signs and symptoms of
hemolysis
Yes=1
No=2
1=less than 12th grade
2=12 grade or higher
3=Literate (able to write
and read)
4=Not able to write or
read Khmer
5=VMW
6=Nurse
7=Physician
1=hands-on training with
the use of RDTs only
2=attended
comprehensive training
workshop
3=Video training
Have mosquito nets
Yes=1 No =2
Tested for malaria/G6PD
deficiency
Yes=1 No =2
2=Storage conditions
3=Equipment and
reagents used correctly
4=Time to results
5=Interpretation of
results
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Appendix F: Study Information-Community Announcement
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Appendix G: Informed Consent Form (Translated to Khmer)
I. STUDY INFORMATION AND INFORMED CONSENT FORM
(Trainee volunteers)
PROTOCOL TITLE: Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase
(G6PD) rapid diagnostic test at community and health center level, Cambodia
INTRODUCTION
You are being asked to participate in a research study entitled “Evaluation of the CareStartTM
glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test at community and health
center level, Cambodia”. In this study, you will be trained to use a new kind of rapid diagnostic
test (RDT), called CareStartTM, a test that is similar to a malaria rapid diagnostic tests. The test
requires a finger prick to collect a small amount of blood from volunteers who desire testing in
order to determine the G6PD activity (normal or reduced) in their blood. Since the testing for
G6PD deficiency is being recommended by national malaria program, in order to provide
antimalarial drug Primaquine safely, we need to identify suitable tests that are easy to use and
can be used in the field settings. Screening of patients for G6PD deficiency is needed in order to
minimize the risks from taking Primaquine. So far CareStartTM has been used successfully only
in special settings, like a lab or hospital. It is hoped that this research will give us better
information about how well the test works when used at a health center or at the village level
when the test is performed by a village malaria worker (VMW) or by military medics. We hope
this research will assist the Cambodia Ministry of Health in determining if G6PD testing can be
done properly at the community level. This study will help establish the appropriate level of care
delivery where this test can be performed successfully following appropriate training.
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STUDY DESCRIPTION Your participation will involve taking part in the 2-day training
workshop focusing on testing for G6PD deficiency, use of Primaquine for malaria treatment and
how to conduct the G6PD screening with RDTs. We anticipate that approximately 104 VMWs
and other health workers will participate in this study. We will conduct training in smaller groups
to facilitate learning environment. Following the workshop training, you will be observed
conducting the G6PD screening tests on patient volunteers in your usual place of work. Each
trainee will test approximately 16 volunteers during the course of study participation, for
anticipated total of 1,600 patient volunteers tested by all trainees who participate in this study.
Each trainee will also be asked to complete pre- and post- training questionnaires to help us
understand current knowledge gaps about the drug Primaquine and about G6PD screening, and
the willingness and acceptability of trainees to use Primaquine and G6PD screening tests in their
place of work. The feedback we get from this study will help us optimize training materials for
healthcare staff who may use Primaquine or G6PD screening tests. Based on the test
performance, we will also be able to assess if the available G6PD screening tests (such as
CareStartTM) are appropriate tests for use in the field settings.
Who is eligible to participate? You have been asked to participate because you are a village
malaria worker or health center staff or medic who manages malaria patients, and work within
the study location. You should seek permission from your supervisor before you participate in
the study. You can participate in this study if: • You are employed as village malaria worker or
healthcare staff likely to diagnose and/or treat patients with malaria (nurses, medics, physicians
are eligible) • You are able to participate in the 2-days workshop training • You agree to a
minimum of 4 days of G6PD screening/testing of volunteers • You have no plans to move
outside study area over the course of next 3 months You cannot participate in this study if: • You
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have known color blindness • Judged by the investigator to be unsuitable for study participation
In order for you to be enrolled in the study, you will also have to sign the consent form stating
your willingness to participate.
What if I do not want to take part in this study? Participation in this study is strictly
voluntary. If you decide not to participate in this study, you will NOT lose any medical or other
benefits for you or your family. If you do not participate in this study, this will not have any
negative effect on your ability to continue working at your current place of work.
How long will this study last: Your participation will last approximately 3 months. This
includes the 2 days’ workshop training and the time needed to recruit sufficient number of
volunteers who will be tested by you for G6PD deficiency. You will be asked to test
approximately 4-8 patient volunteers in one day, for a total of approximately 16 volunteers,
during your study participation. So your active participation is expected to be approximately 6
days (2 days for workshop and 4 days for screening of patients – 4 volunteers per day), spread
over the three-month period. These timelines can be adjusted if recruitment is slower than
anticipated. You should also know that the test takes approximately 10 minutes to complete, per
patient. However, you will also be asked to complete pre- and post-training questionnaires, and
may be asked to participate in a group discussion, which will require additional time. However,
your time participation on any given day will not exceed 8 hrs.
Study Procedures After enrollment you will be asked to provide information about your prior
experience with malaria treatment and asked questions to assess your current knowledge about
Primaquine and G6PD screening tests (pre-training questionnaire). Then you will receive
training on G6PD, screening tests, and Primaquine. Training will also include hands-on
workshop on how to use CareStartTM. After training you will be evaluated using G6PD RDTs
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and you will be asked to answer a few questions about the training and training materials. If
needed, you will receive re-training before going out to check volunteer patients’ G6PD status
using the RDTs at your village.
Check volunteer patients’ G6PD status Within a few days of completing the training, you will
be observed conducting the test on patient volunteers in your usual place of work. You will
conduct the test on 4-8 patients per day to complete approximately 16 G6PD screening tests
during this study. The total number of patients screened may differ slightly between trainees
based on the recruitment of volunteers at each village. If you screen 4 patients a day, it will take
4 days to reach the target of 16. You will also be asked to collect details on patient’s age, sex,
level of education, and contact information for follow-up visit. Then you will be asked to
complete additional post questionnaires about G6PD screening, Primaquine, and RDTs During
your study participation you may be asked to participate in group discussions so we can better
understand current knowledge gaps and the responses in the questionnaires.
Blood Tests During the Study As part of the study, you (trainee) will be asked to do a finger
prick (1 or 2 drops of blood) on another trainee, during the workshop training. This means that
during the workshop training, another trainee may practice finger prick on you as well.
Following the training, you will be asked to do a finger prick to check volunteer patients’ G6PD
status using the RDT, during the observation visits by study team. Separate to the finger prick, a
study team member will collect additional blood (approximately 2 ml) from the patient volunteer
and send it for testing at a lab close to the treatment facility for confirmatory G6PD screening
(for comparison of test results to those with RDTs).
Optional You will NOT be photographed and/or videotaped unless you provide us with consent
allowing us to do so. This part is optional and not required to be able to take part in this study but
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this can be helpful to us in development of future training and education materials.
NOTE: There will be NO photos or videos taken on military installations at any
time.
STOPPING THE STUDY The entire study or a part of the study may be stopped at any time
based on the judgement of the study researchers, the study sponsors, or the ethical committees.
POTENTIAL RISKS Taking blood from your finger during training will cause a brief sharp
pain. The pain is usually mild, and can be described as pinching or pricking your skin with a
sharp object only when we try to collect the blood. This discomfort lasts only a short time,
usually less than 1 minute. All standard precautions will be taken to reduce any potential risk
from accidental exposures to infected blood during finger prick procedure. This risk will be
mitigated by requiring that all trainees wear surgical gloves when performing the finger prick on
volunteers and this will be strictly enforced.
ANTICIPATED BENEFITS There are no other direct benefits to you from participating in this
study other than potentially increasing your medical knowledge. The information from this study
may help other people in the future who have malaria, a disease the kills more than 400,000
people worldwide every year. The study will benefit the community as a whole by providing upto-date information on G6PD diagnosis and malaria treatment which will be provided to the
National Malaria Control program, and other appropriate Cambodian government authorities.
SUBJECT RIGHTS Your participation in this study is voluntary. You may withdraw from the
study at any time without penalty. You must inform the researcher of this decision as soon as
possible. Deciding to leave the study will not influence the availability of future medical care or
other benefits to which you are otherwise entitled. You are not waiving any legal rights by
participating in this study. If you have any questions concerning the study, you may contact Dr.
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Chanthap Lon, Armed Forces Research Institute of Medical Sciences (AFRIMS), No. 5 St. 550,
Phnom Penh, Cambodia. Tel.: +855 12 976 799.
OR
Study team contact number 097 9484 597 or 097 9484 598 If you have any questions about
your rights as a research participant in Cambodia or wish to speak to a person not associated with
this research, you may contact: Dr. Vonthanak Saphonn, Secretary of the Nation Ethics
Committee Health Research IRB#1(NECHR: IRB# 3143) #2 Kim Il Sung Blvd, Khan Tuol Kok,
Phnom Penh. Cambodia, Tel.: 023 880 345, Fax: 023 880 346, E-mail: research03@nchads.org.
The results of this study will be published in scientific journals and the data will be made
available to health care officials in Cambodia, but there will be no specific effort to inform you
of the results of this study. Your name or other identifying information about you will not be
made publicly available except for those trainees who consented to be photographed or
videotaped.
MEDICAL CARE FOR RESEARCH RELATED INJURY If you are injured as a direct
result of your participation in this study, you should inform study team immediately. You will
receive medical care for that injury at the appropriate local medical facility, following current
standard of care, at no cost. The sponsor of this study is responsible for the medical costs. This
medical care provision does not constitute a waiver or release of your legal rights. You will not
receive additional compensation for this injury. If you have questions about this medical care,
talk to the Principal Investigator for this study.
COMPENSATION For VMWs, HC staff, and/or medics the compensation will be 56,000
Cambodian Riel (approximately US $14/day) for each day of training (2 full days) and the same
amount (~$14) on the days they are screening volunteers for G6PD deficiency (estimated as 4
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days for each trainee). If the trainee requires more than 4 days to
screen 16 volunteers, the compensation on days of screening will be limited to
4 days only. The compensation for VMWs/HC staff and medics who will screen volunteers for
G6PD deficiency, takes into consideration the government set local per diem rates that is
approximately $14/day. Compensation for all volunteers also takes into consideration lost
earnings, meals and incidentals arising from participation.
CONFIDENTIALITY Your research record and personal information such as name, address,
date of birth, etc., will be kept confidential and will not be made available to individuals or
organizations who are not involved with the study, unless required by applicable law. If the
results of this study are published in the medical literature, your identity will not be revealed. By
signing this consent form, you are granting permission for your medical records collected under
this study, to be reviewed by the study staff, authorized representatives of ethical committees
who have approved this research, other regulatory authorities reviewing this study, and the study
Sponsor’s representatives. All of these are responsible to ensure that the research is conducted in
an ethical, safe, and legal manner to protect your rights and your safety. Your record includes
participation date, study code, name, age, sex, contact address and the reason if you cannot
participate in the study will be kept in a secure location by the investigators for 5 years at
AFRIMS office in Cambodia once the study is completed. The study data may be entered into an
electronic database, which will be password protected. The review of these medical records may
be in respect to this study and any further research that may be conducted in relation to it. Your
records may be reviewed, as described above, even if you withdraw from the study. For military
volunteers (medics), complete confidentiality cannot be guaranteed because information bearing
on a soldier’s health may be required to be reported to appropriate medical or command

49
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING
authorities. However, this risk is mitigated as no highly sensitive information is being asked of
the volunteers except general question about overall health status.

CERTIFICATES OF CONSENT I, the undersigned, have read, or have had read to me
in language understandable to me, the above information. Before signing this consent form, a
member of the research team has explained to me in detail, and I understand, the objectives,
procedures, and risks possibly associated with this study as well as the benefits. The research
team has answered all my questions willingly, clearly, without concealment and to my
satisfaction. I have a right to withdraw from the study at any time. My participation in this
research is voluntary. I can choose not to participate. Refusal or discontinuation of my
participation will involve no penalty or affect the standard care that I would otherwise expect to
receive. If I join this project, I can ask the researcher or his representative at any time about the
project. I will be provided with a copy of this consent form. I understand that I can choose to be
photographed and/or videotaped during this study. If refused, I can still take part in the study.
The research team has confirmed to keep any data concerning myself confidential and my name
and identity will not be revealed in any reports. Only authorities involving in the support or
monitoring of this project may be permitted to examine my data. I consent of free will for the
following (check one):
All required procedures to include permission to be photographed and/or videotaped
All study procedures WITHOUT being photographed and/or videotaped

________________________
__________ ______________________
Signature of the volunteer Date Print name

I have explained the purpose of this study to the volunteer

and have answered all of the questions. ________________________
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__________ ______________________
Signature of person obtaining consent Date Print name

WITNESS I have witnessed the accurate informed consent process to the volunteer, and the
individual has had the opportunity to ask questions. I confirm that the individual has given
consent freely. _______________________
__________ _________________________
Signature of the witness /ombudsman Date Print name

Copy provided to the participant _____________ (initials of person obtaining consent)
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APPENDIX H: Training Steps
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Appendix I: Supervisor Permission Approval form (Khmer).

Translated from English Supervisor Approval Form-Trainee: version 13 October 2017

កាអនុញ្ តរបស់អនកគ្ប់គ្ង
ខ្ញុំង់ចូលរួមក្ងងឿរសិក្ា ន ងាា ែាលមាចុុំងន ងាងថ “ កាវាតម្ៃាលងលលតស្សហ័ស្ាសី ្ាាិភីឌី
( G 6PD)មស្ា្ ា់ ស្គ្់ ឈាស្គ្មងៅតាសគៃមៃ៍ ៃាា ងមណ្ លស្ ខភា ក ង ន ងស្គ្ ស កម ព
ជា ’ ។

ខ្ញុំ ត្ាួរពិ ាិងរើង ឿលវភាិ ន ត្ារតិឿរណៃ៍សត្ា ា់ងាឿរសិក្ា ន ងា ន ងាឿជា្ថ ងាឿរចូលរួមរបស់ខ្ញុំាង
មិ ងរំៀ ែាល់រួនាាីរបស់ខ្ញុំទ។
ខ្ញុំ ពិ ាិងរើ ន ងាងវញិ ាូងវឿរសិក្ា ាិងងឿលវភាិ របស់ខញុំ្ ាួ ាងនមបញ្ងាងាឿរ ែាាូងចំៀងនតម ខ្ញុំ្ាូវ
ងាឿងរឿរអ ាុ ស្ញពីងារ់ែនងាងមបីចូលរួមក្ងងឿរសិក្ា ។
ង ប់ចមលងន ទតង់ន ងាា ាងត្ាូវបាដា្នងា ក្ងឯក្ា ងាឿរសិក្ា របស់ខ្ញ ។
___________________________________
រថនងលំៀរបស់សិឿងខឿម ងាឿលបរិនងចទ( d /MM/y )
_____________________
ន ា្ ងាា បស់សិឿងខឿម
_______________________________________
_______________
អនកគ្ប់គ្តាង ឋាា ាុ គ្៖ម
ខ្ញុំល់ថ ងាឿរចូលរួមក្ងងឿរសិក្ា ន ងាា ាងត្ាូងវឿរនពលនវលាបស់បុគ្គ្លិកងនងលអាមាផលប ងា
ព់ ែាងល់ឿរអ ាុ វរត ាៃ៍របស់ពួកគ
ខ្ញុំ ាុ ស្ញនងលឿរចូលរួមរបស់បុគ្គ្លិកងនងលក្ងងឿរសិក្ា ន ងាា
__________________________________
រថនងលំៀរបស់អនក្ាបា់តង ងាឿលបរិនងចទ
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Appendix J: Pre-Training and Post Training questionnaires

TRAINEE (HCWs/VMW/Medic)
(Complete PRIOR to training)
Visit Date: ______________________________
(dd/MM/yy)
[Please Check () or Mark (X) to select your answer; if more than one answer can be selected, it will be stated in the question;
for all other, only ONE answer can be selected]
NOTE: You are not expected to know the answers to all the questions. If you do not know the answer, you can select, I do
NOT KNOW. The information you provide will help us develop future teaching materials to address the knowledge gaps.

DEMOGRAPHICS
1. Age: _______ (Years)
2. Sex:  Male

 Female

3. Occupation:
 Physician
 Nurse
 Lab technician
 Village Malaria Worker
 Medic
 Other________________________________________________________
4. Highest education level completed:
 Primary School (grades 1-6)
 Secondary (grades 7-9)
 High-school (grades 10-12)
 College
 Post-graduate degree (for example PhD or MD)
5. The number of years I have been working at my current position (i.e
nurse/VMW/medic)
 <1 year
 3 years to <5 years
6. In what setting do you normally work?
 Hospital

 1 year to <3 years
 5 years or more
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 Health center/Health post
 Community/malaria village worker
 Military

KNOWLEDGE ASSESSMENT PRIMAQUINE AND G6PD
SCREENING
[Please Check () or Mark (X)]

7. Have you heard about drug Primaquine (PQ)?
 Yes

 No

8. Do you know what Primaquine is used for?
 Yes (specify): _________________________________________________
 No
9. Do you know of any benefits of Primaquine for people with P. vivax malaria?
 Yes (specify): _________________________________________________
 No
10. Do you know of any benefits of Primaquine for people with P. falciparum malaria?
 Yes (specify): _________________________________________________
 No
11. Do you know of any risks or side effects associated with taking Primaquine?
 Yes (specify): _________________________________________________
 No
12. Have you ever prescribed Primaquine?
 Yes, for what disease: ___________________________________________
 No
13. Have you ever treated a patient with acute hemolysis or severe anemia?
 Yes

 No

14. Have you heard of a condition known as Glucose-6-phosphate dehydrogenase (G6PD)
deficiency?
 Yes

 No
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15. Primaquine should NOT be used if the patient has (select all that apply):
 Headache
 Fever
 Malaria
 Mild abdominal pain
 G6PD deficiency  I do not know
16. When taking Primaquine, patient should be monitored for the following? (select all that
apply):
 Pallor

 Dizziness

 New onset or worsening fatigue

 Yellow skin or eyes

 Back pain

 Shortness of breath

 Change in color of your urine to dark, tea color
 Monitoring is NOT needed

 I do not know

17. Per current treatment recommendations in Cambodia, who should be treated with
Primaquine? (select all that apply):
 Anyone with falciparum malaria (including G6PD deficient patients)
 Anyone with falciparum malaria (MUST have G6PD normal results)
 Anyone with vivax malaria (including G6PD deficient patients)
 Anyone with vivax malaria (MUST have G6PD normal results)
 I do not know
18. What is the benefit of treatment with Primaquine? (select all that apply):
 Primaquine kills the parasites that hide in the liver
 Primaquine can lower the risk of having vivax malaria recurrence
 Primaquine can be used for malaria treatment as monotherapy
 I do not know
19. What may happen if patient accidentally takes Primaquine when he/she is G6PD deficient?
(select all that apply):
 Patient may become sick from the side effects of Primaquine
 Patient may develop weakness or sudden change in the color of the urine
 Red blood cells that carry oxygen can get damaged

56
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING
 Nothing will happen because Primaquine is very safe
 I do not know
20. The risk of side effects with Primaquine can be reduced with G6PD testing:
 True

 False

 I do NOT know

21. Primaquine is recommended for cure in patients with vivax malaria if they have normal
G6PD test:
 True

 False

 I do NOT know

22. Primaquine is REQUIRED to be cured of falciparum malaria:
 True

 False

 I do NOT know

23. If a patient has falciparum malaria, they can take 1 (one) dose of Primaquine without
checking their G6PD status.
 True

 False

 I do NOT know

24. Who should be tested for G6PD deficiency using the Rapid Diagnostic Test (i.e
CareStartTM)?
 Males

 Females

 Both males and females

25. How will you prescribe Primaquine for adult patient with vivax malaria (G6PD
normal)?
 14 tablets to take in one day
 One tablet taken every day, until patient feels better
 1 tablet a day for 14 days to complete full 2-week course, even if all malaria symptoms
disappear at the end of week one
 1 tablet on the first day of treatment only
 I do not know
26. After I take Primaquine for vivax malaria, which of the following is true:
 I can still get vivax malaria again if I get bitten by an infected mosquito in the future
 I am permanently protected from vivax malaria after I take Primaquine
 I do not know
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27. Taking 1 dose (1 tablet) of Primaquine if patient has falciparum malaria helps the community
by lowering the risk of malaria spread.
 True

 False

 I do NOT know

28. Taking 1 dose (1 tablet) of Primaquine by a patient with falciparum malaria is safe, without
need for G6PD testing.
 True

 False

 I do NOT know

29. Taking 2 weeks course of Primaquine by a patient with vivax malaria is safe, without G6PD
testing.
 True

 False

 I do NOT know

30. If urine suddenly becomes dark, cola-colored (shown below), the patient should:
 Seek medical care immediately
 Monitor this situation over the next 3-5
days
 Continue taking Primaquine to make sure can be
cured from malaria
 I don’t know
31. Pregnant women and women who are breastfeeding can take Primaquine safely.
 True

 False

 I do NOT know

32. What is the benefit of Primaquine treatment for a patient with P. falciparum?
 No benefit, treatment is NOT recommended
 Benefit is small
 The community can benefit by lowering the risk of malaria transmission to
others
 I don’t know
33. How beneficial is Primaquine treatment for a patient with P. vivax?
 No benefit, treatment is NOT recommended
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 Benefit is small
 Majority of patients can benefit from treatment (it is required for cure)
 I don’t know
34. How long do you have to wait before reading G6PD RDT results (CareStartTM)?
 2 min
 10 min
 I don’t know

 5 min
 15 min

35. What can affect the test performance of G6PD screening test such as CareStartTM (select all
that apply):
 Temperature >32 degrees
 Novice user not familiar with the color interpretation
 Reading of the test at 15 mins rather than 10 mins
 I don’t know
36. When interpreting the G6PD RDTs, the patient is G6PD deficient when: (SELECT ALL
THAT APPLY)?
 The color in the reading window is WHITE
 The color in the reading window is PURPLE
 The color in the reading window is VERY FAINT PURPLE
 I don’t know
37. A male patient has G6PD result shown below, what do you recommend next?
 Treatment with Primaquine
 Counsel the patient that he/she is G6PD deficient
 Repeat the test
  I don’t know
38. A male patient has G6PD result shown below, would you recommend
Primaquine?

 Yes
 No
I
don’t
know
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39. A mother comes to the clinic and informs you that she is feeling tired and her lips look pale
after taking her husband’s anti-malaria treatment. On inquiry, you discover he was prescribed
Primaquine a week ago and felt better quickly, so he shared his remaining medications with
his wife who he thought also had malaria. What is the most important step you should take at
this time?
 Prescribe additional tablets of Primaquine so the patient has enough to finish 2 weeks’
course
 Discharge home with instruction to return if she develops a fever
 Immediately refer to the nearest hospital for urgent evaluation
 I don’t know

ACCEPTABILITY OF G6PD TESTING AND PRIMAQUINE
TREATMENT
[Please Check () or Mark (X) to select your answer]
G6PD TESTING
40. How reliable is G6PD screening test for male patients (Rapid Diagnostic Test such as
CareStartTM)?
Not reliable
Very Reliable
1
2
3
4
5
6
7
 I don’t know
41. How reliable is G6PD screening test for female patients (Rapid Diagnostic Test such as
CareStartTM)?
Not reliable
Very Reliable
1
2
3
4
5
6
7
 I don’t know
42. G6PD screening tests should be made available at the following locations (select all that
apply):
 In the village, testing by Village Malaria Worker
 Health clinic
 Hospital
43. Are you willing to test patients for G6PD deficiency every time they have malaria?
 Yes
 No
 I don’t know
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44. How comfortable are you providing Primaquine treatment based on the G6PD Rapid
Diagnostic Tests only:
Not comfortable
Very comfortable
1
2
3
4
5
6
7
 I don’t know
45. How willing are you to use G6PD screening tests that can misclassify few patients who are
deficient as being normal (due to limitations, some tests many give incorrect result)?
Not acceptable
Acceptable
1
2
3
4
5
6
7
 I don’t know
46. In your view, what is the likelihood of G6PD rapid test showing wrong result?
Very low
Very high
1
2
3
4
5
6
7
 I don’t know
47. What are your thoughts about G6PD screening with RDTs?
☐ I am supportive, reason:
☐ I am not supportive, reason:
☐ I am not sure
PRIMAQUINE RISK
48. How willing are you to give Primaquine to a patient with P. vivax malaria and normal
G6PD test?
Not willing
1
2

3

4

5

6

Willing
7

 I don’t know
49. How willing are you to give Primaquine single dose treatment for P. falciparum for a patient
NOT screened for G6PD deficiency?
Not willing

Willing
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1

2

3

4

5

6

7

 I don’t know
Comments:
____________________________________________________________
50. How willing are you to give 2 week course treatment of Primaquine to MALE patients with
vivax malaria and normal G6PD status (based on CareStartTM RDT)?
Not willing
1

Willing
2

3

4

5

6

7

 I don’t know
51. How willing are you to give 2 week course treatment with Primaquine to a FEMALE patient
with vivax malaria and normal G6PD status (based on CareStartTM RDT)?
Not willing
1

Willing
2

3

4

5

6

7

 I don’t know
52. In your view, what is the risk of single dose treatment with Primaquine, when test shows
you are G6PD deficient (based on CareStartTM RDT)?
No risk

Very high risk
1

2

3

4

5

6

7

 I don’t know
53. In your view, what is the risk of single dose treatment with Primaquine, when test shows
you are G6PD normal (based on CareStartTM RDT)?
No risk
1

Very high risk
2

3

4

5

6

7
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 I don’t know
54. In your view, what is the risk of 2 week course treatment with Primaquine when test shows
you are G6PD deficient (based on CareStartTM RDT)?
No risk

Very high risk

1

2

3

4

5

6

7

 I don’t know
55. In your view, how high is the risk of 2 week course treatment with Primaquine, when test
shows you are G6PD normal (based on CareStartTM RDT)?
No risk

Very high risk

1

2

3

4

5

6

7

 I don’t know
56. Please select if the treatment with Primaquine results in greater risk or benefit, for the
following scenarios:
Malaria

Primaquine

G6PD
status

P.falciparum

single dose
(1 tablet)
single dose
(1 tablet)
2 week
course
2 weeks
course

deficient

P.falciparum
P.vivax
P.vivax

Greater
benefit

Greater
risk

normal
deficient
normal

57. How confident are you in performing RDTs for G6PD screening?
Not confident
1

2

Very confident
3

4

5

6

7

I
don't
know

63
G6PD CARESTART™ RAPID DIAGNOSTIC TESTING

 I don’t know
58. How confident are you in your interpretation of the results of the G6PD screening test
based on the color change (CareStartTM RDT kit)
Not confident
1

2

Very confident
3

4

5

6

7

 I don’t know
59. Do you have any additional comments about Primaquine safety or G6PD testing?
 Yes:
_____________________________________________________________
 No
60. Which questions did you find confusing or in your view, should be removed (list by
number)?
_____________________________________________________________________
Completed by: _____________________
(Trainee)
Reviewed form completeness by: _____________________
(Researcher or Designee)
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TRAINEE (HCWs/VMW/Medic)
(Complete AFTER training)
Visit Date: ______________________________
(dd/MM/yy)
Please Check () or Mark (X) to select your answer; if more than one answer can be
selected, it will be stated in the question; for all other, only ONE answer can be
selected

REVIEW OF THE TRAINING
1. The scope of the material and training was relevant to my job
Disagree
1

Strongly Agree
2

3

4

5

6

7

2. The material was well organized and easy to understand
Disagree
1

Strongly Agree
2

3

4

5

6

7

3. The examples presented helped me understand the content
Disagree
1

Strongly Agree
2

3

4

5

6

7

4. The hands-on training workshop on the use of G6PD RDTs added value to my learning
Disagree
1

Strongly Agree
2

3

4

5

6

7

5. The use of known G6PD controls added to my learning and I would recommend it in future
workshops
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Disagree
1

Strongly Agree
2

3

4

5

6

7

6. What is the OPTIMAL number of known G6PD controls that should be used for practice in
the workshop?
 3 normal, 3 deficient, 3 intermediate
 Fewer number of controls can be used for training purposes
 Greater number of controls would be beneficial to become more familiar with the
possible color changes
7. The use of AccessBio Reference Color Card is helpful in test interpretation of CareStartTM
RDT
Disagree
1

Strongly Agree
2

3

4

5

6

7

8. I would recommend this training to others
Disagree
1

Strongly Agree
2

3

4

5

6

7

9. The content was presented in a way that allowed for sufficient learning
Disagree
1

Strongly Agree
2

3

4

5

6

7

10. The length of training was:
 Too long

 Too short

 Just about right
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KNOWLEDGE ASSESSMENT PRIMAQUINE AND G6PD
SCREENING
[Please Check () or Mark (X)]

11. Do you know what Primaquine is used for?
 Yes (specify): _______________________________________________________
 No
12. Do you know of any benefits of Primaquine for people with P. vivax malaria?
 Yes (specify): _______________________________________________________
 No
13. Do you know of any benefits of Primaquine for people with P. falciparum malaria?
 Yes (specify): _______________________________________________________
 No
14. Do you know of any risks or side effects associated with taking Primaquine?
 Yes (specify): _______________________________________________________
 No

SCORED QUESTIONS 15 TO 39
15. Primaquine should NOT be used if the patient has (select all that apply):
 Headache
 Fever
 Malaria
 Mild abdominal pain
 G6PD deficiency
 I do not know
16. When taking Primaquine, patient should be monitored for the following (select all that
apply):
 Pallor
 Dizziness
Yellow skin or eyes
 New onset back pain
 New onset or worsening fatigue
 Shortness of breath
 Change in color of your urine to dark, cola color
 Monitoring is NOT needed
 I do not know
17. Per current treatment recommendations, who should be treated with Primaquine (select all
that apply):
 Anyone with falciparum malaria (G6PD normal and G6PD deficient patients)
 Anyone with falciparum malaria (MUST have G6PD normal results)
 Anyone with vivax malaria (G6PD normal and G6PD deficient patients)
 Anyone with vivax malaria (MUST have G6PD normal results)
 I do not know
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18. What is the benefit of treatment with Primaquine (select all that apply):
 Primaquine kills the parasites that hide in the liver
 Primaquine can lower the risk of having vivax malaria recurrence
 Primaquine can be used for malaria treatment as monotherapy
 I do not know
19. What may happen if patient accidentally takes Primaquine when he/she is G6PD
deficient?
 Patient may become sick from the side effects of Primaquine
 Patient may develop weakness or sudden change in the color of the urine
 Red blood cells that carry oxygen can get damaged
 Nothing will happen because Primaquine is very safe
 I do not know
20. The risk of side effects with Primaquine can be reduced with G6PD testing:
 True
 False
 I do NOT know
21. Primaquine is recommended for cure in patients with vivax malaria if they have normal
G6PD test:
 True

 False

 I do NOT know

22. Primaquine is REQUIRED for cure from falciparum malaria:
 True

 False

 I do NOT know

23. If a patient has falciparum malaria, they can take 1 (one) dose of Primaquine without
checking their G6PD status.
 True

 False

 I do NOT know

24. Who should be tested for G6PD deficiency using the Rapid Diagnostic Test? (i.e
CareStartTM):
 Males

 Females

 Both males and females

25. How will you prescribe Primaquine for adult patient with vivax malaria (G6PD
normal):
 14 tablets to take in one day
 One tablet taken every day, until patient feels better
 1 tablet a day for 14 days to complete full 2-week course, even if all malaria symptoms
disappear at the end of week one
 1 tablet on the first day of treatment only
 I do not know
26. After I take Primaquine for vivax malaria, which of the following is true:
 I can still get vivax malaria again if I get bitten by an infected mosquito in the future
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 I am permanently protected from vivax malaria after I take Primaquine
 I do not know
27. Taking 1 dose (1 tablet) of Primaquine if patient has falciparum malaria helps the community
by lowering the risk of malaria spread.
 True

 False

 I do NOT know

28. Taking 1 dose (1 tablet) of Primaquine by a patient with falciparum malaria is generally safe,
for patients with normal and G6PD deficient status.
 True

 False

 I do NOT know

29. Taking 2 weeks course of Primaquine by a patient with vivax malaria is safe, without G6PD
testing.
 True

 False

 I do NOT know

30. If urine suddenly becomes dark, cola-colored (shown below), the patient should:
 Seek medical care immediately
 Monitor this situation over the next 3-5
days
 Continue taking Primaquine to make sure
can be cured from malaria
 I do NOT know
31. Pregnant women and women who are breastfeeding can take Primaquine safely.
 True

 False

 I do NOT know

32. What is the benefit of Primaquine treatment for a patient with P. falciparum?
 No benefit, treatment is NOT recommended
 Benefit is small
 The community can benefit by lowering the risk of malaria transmission to
others
 I do NOT know
33. How beneficial is Primaquine treatment for a patient with P. vivax?
 No benefit, treatment is NOT recommended
 Benefit is small
 Majority of patients can benefit from treatment (it is required for cure)
 I do NOT know
34. How long do you have to wait before reading G6PD RDT results (CareStartTM)?
 2 min
 5 min
 10 min
 15 min
 I don’t know
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35. What can affect the test performance of G6PD screening test such as CareStartTM? (select all
that apply):
 Temperature >32 degrees
 Novice user not familiar with the color interpretation
 Reading of the test at 15 mins rather than 10 mins
 I do NOT know
36. When interpreting the G6PD RDTs, the patient is G6PD deficient when: (SELECT ALL
THAT APPLY)?
 The color in the reading window is WHITE
 The color in the reading window is PURPLE
 The color in the reading window is VERY FAINT PURPLE
 I do NOT know
37. A male patient has G6PD result shown below, what do you recommend next?
 Treatment with Primaquine
 Counsel the patient that he/she is G6PD
deficient
 Repeat the test
  I don’t know
38. A male patient has G6PD result shown below, would you recommend
Primaquine?
 Yes
 No
I
don’t
know
39. A mother comes to the clinic and informs you that she is feeling tired and her lips look pale
after taking her husband’s anti-malaria treatment. On inquiry, you discover he was prescribed
Primaquine a week ago and felt better quickly, so he shared his remaining medications with
his wife who he thought also had malaria. What is the most important step you should take at
this time?
 Prescribe additional tablets of Primaquine so the patient has enough to finish 2 weeks’
course
 Discharge home with instruction to return if she develops a fever
 Immediately refer to the nearest hospital for urgent evaluation
 I do NOT know

ACCEPTABILITY OF G6PD TESTING AND PRIMAQUINE
TREATMENT
[Please Check () or Mark (X) to select your answer]
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G6PD TESTING

40. How reliable is G6PD screening test for male patients (Rapid Diagnostic Test such as
CareStartTM):
Not reliable
Very Reliable
1
2
3
4
5
6
7
 I do NOT know
41. How reliable is G6PD screening test for female patients (Rapid Diagnostic Test such as
CareStartTM):
Not reliable
1

Very Reliable
2

3

4

5

6

7

 I do NOT know
42. G6PD screening tests should be made available at the following locations (select all that
apply):
 In the village, testing by Village Malaria Worker
 Health clinic
 Hospital
43. Are you willing to test patients for G6PD deficiency every time they have malaria?
 Yes

 No

 I do NOT know

44. How comfortable are you providing Primaquine treatment based on the G6PD Rapid
Diagnostic Tests only:
Not comfortable
1
2

3

4

5

Very comfortable
6
7

45. Are you willing to use G6PD screening test if it can misclassify few patients who are
deficient as being normal (due to test limitations, some tests many give incorrect result)?
Not acceptable
1

Acceptable
2

3

4

5

6

7
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 I do NOT know
46. In your view, what is the likelihood of G6PD rapid test showing wrong result?
Very low
1

2

3

4

5

6

Very high
7

 I do NOT know
47. What are your thoughts about G6PD screening with RDTs?
☐ I am supportive, reason:
☐ I am not supportive, reason:
☐ I am not sure
PRIMAQUINE RISK

48. How willing are you to give Primaquine to a patient with P. vivax malaria and normal
G6PD test?
Not willing
1
2

3

4

5

6

Willing
7

 I do NOT know
49. How willing are you to give Primaquine single dose treatment for P. falciparum for a patient
NOT screened for G6PD deficiency?
Not willing
1

Willing
2

3

4

5

6

7

 I do NOT know
Comments: _____________________________________________________________
50. How willing are you to give 2 week course treatment of Primaquine to MALE
patients with vivax malaria and normal G6PD status (based on CareStartTM RDT)?
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Not willing
1

Willing
2

3

4

5

6

7

 I do NOT know
51. How willing are you to prescribe 2 week course treatment with Primaquine to FEMALE
patients with vivax malaria and normal G6PD status (based on CareStartTM RDT)?
Not likely
1

Very Likely
2

3

4

5

6

7

 I do NOT know
52. In your view, what is the risk of single dose treatment with Primaquine, when test shows
you are G6PD deficient (based on CareStartTM RDT)?
No risk

Very high risk

1

2

3

4

5

6

7

 I do NOT know
53. In your view, how high is the risk of single dose treatment with Primaquine, when test
shows you are G6PD normal (based on CareStartTM RDT)?

No risk
1

Very high risk
2

3

 I do NOT know

4

5

6

7
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54. In your view, how high is the risk of 2 week course treatment with Primaquine when test
shows you are G6PD deficient (based on CareStartTM RDT)?
No risk

Very high risk

1

2

3

4

5

6

7

 I do NOT know
55. In your view, how high is the risk of 2 week course treatment with Primaquine, when test
shows you are G6PD normal (based on CareStartTM RDT)?
No risk

Very high risk

1

2

3

4

5

6

7

 I do NOT know
56. Please select if the treatment with Primaquine results in greater risk or benefit, for the
following scenarios:
Malaria

Primaquine

G6PD
status

P.falciparum

single dose
(1 tablet)
single dose
(1 tablet)
2 week
course
2 weeks
course

deficient

P.falciparum
P.vivax
P.vivax

Greater
benefit

Greater
risk

normal
deficient
normal

57. How confident are you in performing RDTs for G6PD screening correctly?
Not confident
1

2

Very confident
3

 I do NOT know

4

5

6

7

I
don't
know
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58. How confident are you in your interpretation of the results of the G6PD screening test
based on the color change (CareStartTM RDT kit)
Not confident
1

2

Very confident
3

4

5

6

7

 I do NOT know
59. Do you have any additional comments?
 Yes: _____________________________________________
 No
60. Which questions did you find confusing or in your view, should be removed (list the
corresponding numbers)?
Completed by: _____________________
(Trainee)

Reviewed form completeness by: _____________________
(Researcher or Designee)
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Appendix K: CareStart™ Equipment
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Point out the expiry date on the test packet, but do not read the date.
Pass the test packet around and ask each participant to look at it.
Allow participants to go through the process of hands-on training to ensure they can read
expiration date and follow the steps for processing the sample.
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APPENDIX
Steps for testing G6PD Status in field setting using CareStart™
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APPENDIX L: G6PD normal Vs deficient among Males/Females

(Global Malaria
Program, 2016)

APPENDIX M: Flow Chart
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Appendix N1: G6PD Trainee Checklist
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Appendix O: PATIENT COUNSELING SCRIPT (ENGLISH)

INFORMATION ABOUT PRIMAQUINE & G6PD SCREENING
G6PD deficiency
Some people have a low amount of a
substance called glucose-6-phosphate
dehydrogenase (G6PD) in the cells that
carry oxygen in the blood around the body.
These people have what is called G6PD
deficiency. Most people with low G6PD
levels never know they are different, and
they do not show symptoms unless they take
certain medications, such as Primaquine.

G6PD normal

Primaquin

G6PD deficient

If the patient has a low amount of G6PD, their red blood cells can get broken or burst more easily.

Current malaria treatment
recommendations in Cambodia
Current treatment guidelines in Cambodia
recommend that all malaria patients receive
antimalarial drugs called artemisinin-based
combination therapy (ACT) for 3 days.
Patients with malaria should also receive
treatment with Primaquine, as long as they
have normal levels of G6PD in their red blood
cells.

It is recommended that G6PD normal patients who have vivax malaria receive treatment with
Primaquine every day for 14 days. Patients who have falciparum malaria should receive a single
dose of Primaquine. However, all patients require testing to confirm they have normal G6PD
levels, before receiving treatment with Primaquine.
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Why is Primaquine recommended
for malaria treatment?
If a patient has vivax malaria and does NOT get treatment with Primaquine, they can have parasites
that stay hidden in the liver and enter blood several months later, which will make the patient sick
again with malaria symptoms.
To get rid of these parasites from the liver, the patient needs to take Primaquine.

For patients who have falciparum malaria, it is recommended that
they take one dose of Primaquine in order to reduce the risk of
transmission of malaria to other people. This means fewer people
will be able to transmit malaria in the community, so the risk of
getting malaria when they get bitten by a mosquito may be lower.
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G6PD testing was not available in
Cambodia, so Primaquine was not used,
but the National Malaria Program (CNM)
would like to make testing and Primaquine
more widely available for malaria patients,
in support of Cambodia malaria
elimination strategy.

Primaquine

G6PD test kit

What are the risks of treatment with Primaquine?
For patients with NORMAL G6PD levels, taking Primaquine is generally very well tolerated without any
issues.
But taking Primaquine is NOT recommended for people with G6PD deficiency, as the breakdown of the
red blood cells can make them ill. The most common symptoms are fatigue, shortness of breath after
activity, rapid breathing, pallor, and increased heart rate, yellowing of skin and eyes, or dark, tea colored
urine or back pain. In most cases, this can be corrected by stopping Primaquine treatment when these
symptoms develop. Patients with NORMAL G6PD levels are very unlikely to develop these symptoms
with Primaquine.

If someone’s G6PD levels are very low, Primaquine treatment could result in a large number of their
red blood cells being destroyed. Therefore, in rare cases, some patients treated with Primaquine may
need a blood transfusion to replace the red blood cells that burst after Primaquine treatment. This is
very unlikely for patients with normal G6PD levels

STOP Primaquine
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The risks of Primaquine treatment are based on patient’s G6PD level, how many doses of Primaquine
they take and other factors. Risk can be minimized if a patient has normal or near normal levels of
G6PD.
The risk from Primaquine treatment is also considered very low for falciparum patients since they
only have to take a single dose. Single dose treatment is unlikely to result in significant destruction
of red blood cells, even for patients with low levels of G6PD. It is therefore acceptable to take
SINGLE dose of Primaquine for falciparum malaria without G6PD testing.

Lack of treatment with Primaquine in patients with vivax malaria also poses risks to patients as this can
result in frequent recurrences of vivax malaria. Having malaria recurrence frequently can affect your
ability to work or take care of your family.

What are the benefits of PQ treatment?
It is suspected that many patients have vivax recurrence due to lack of treatment with Primaquine,
which allows the hidden parasites in the liver to enter the patient’s blood many times. Taking
Primaquine when a patient is diagnosed with vivax will kill and eliminate hidden parasites in their
liver and make them less likely to have recurrence of the infection. However, it is still possible for
a patient to get vivax in the future if they get bitten again by an infected mosquito.
Taking Primaquine when a patient has falciparum malaria will make them less likely to transmit
the infection to other people, which may reduce their own risk of getting infected again.
Limitations of the current tests for G6PD screening:
There are different tests for G6PD deficiency but most of them are not suitable for use outside of
a highly specialized laboratory setting. The test for G6PD deficiency which is being used today
comes with limitations as outlined below:
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1. The rapid diagnostic test for G6PD deficiency
requires interpretation of a color change, which can
sometimes be difficult, or color change can be
misinterpreted even by highly trained medical staff.
2. The reliability of the test may be compromised if the
testing is done in the room with more than 32 degrees
Celsius.
3. The rapid diagnostic test can only tell if a patient has
NORMAL or LOW levels of G6PD. These tests
cannot tell how much of the G6PD enzyme the
patient has.
Therefore, it is recommended that even with
NORMAL G6PD test result, all patients are
monitored for possible side effects from taking Primaquine.

Understanding your test results:
If your test result is normal it means you
should have sufficient levels of the G6PD
enzyme to receive Primaquine safely

If the test shows you are G6PD deficient, this means that taking Primaquine for 14 days could
damage some of your red blood cells and might make you feel sick. This can manifest as you
being pale, having shortness of breath with activity, having a yellow pigmentation of the skin or
eyes, or tea-colored urine. So treatment with Primaquine is not recommended for vivax malaria
when you are G6PD deficient. However, single dose of Primaquine for falciparum malaria is
normally tolerated even in patients with G6PD deficiency; therefore, it is recommended to reduce
risk of transmission to others.

Given the limitations of the tests, if you are given
Primaquine and develop the above mentioned
symptoms or any new symptoms within 2 weeks of
taking Primaquine, you should visit your doctor
immediately. If your local health center is closed,
then you should go to the nearest hospital.
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APPENDIX P: Descriptive Statistical Table for Trainees

Variables
Trainee
VMW
Nurse
Other
Age Group Trainees
<30yrs
31-50yrs
>51yrs
Gender
Male
Female
Educational Level
Primary grade
(1-6)
Secondary
High school
College graduate
Medical Doctor

Total sample
94
68
21
5

(%)
100
72.3
22.3
5.4

29
51
14

30.9
54.3
14.9

40
54

42.6
57.4

39

41.5

30
14
8
1

31.9
14.9
8.5
1.1
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Appendix Q: Results from Study
Trainee score Pre and Post Training based on Years of Experience

91.33

100
90
80
70
60
50
40
30
20
10
0

91.2

89.5
78.67

p<0.001
38

37.5

41

< 1 year

1- < 3 years

3- < 5 years

37.33

>=5 years

Years of Experience
pre-training knowledge out of 25
post-training knowledge out of 25

II

Percentage proportion in profession

Percentage mean marks

I.

100

83.33

80

75

p-Value=0.57

80

60
40
20
0

16.67
0
0
< 1 year

41.67 41.67

25
0

0

1- < 3 years

8.33 8.33

13.33
6.67

3- < 5 years

>=5 years

Years in Experience
Midwife

Nurse

Other

0

VMW
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III

IV
The percentage mean score knowledge pre-training and post-training (p<0.001)

Pre-Training
Post-Training
Willingness to test for
G6PD when a patient
is diagnosed with
malaria
Level of comfort in
giving PQ based on
G6PD RDT results
Level of comfort in
giving PQ to a patient
with P.v and normal
G6PD test
Willingness to give a
patient PQ single
dose for Pf without
G6PD screening

VMWs
Nurses
34%
56.4%
88.71%
90%
PRE-TRAINING
56.3% (53/94)

Other
34%
96%
POST-TRAINING
80.8%(76/94)

39.3% (37/94)

72.3% (68/94)

36.1%(34/94)

80.0% (76/94)

20.2%( 19/94)

84% (79/94)

P r e -T r a in in g k n o w le d g e s c o r e

Acceptability to Test for G6PD Pre and Post Training
0

0

0

0

0

0

0

0

0

2

5

5

5

5

2

2

2

0

0

0

5

5

5

5

4

4

4

2

2

2

2

1

1

1

1

1

7

9

9

8

7

7

6

5

5

4

0

9

9

7

7

1

1

1

7

7

5

5

8

7

7

7

4

4

4

4

5

5

3

3

3

3

0

0

0

7

6

4

3

0

9

5

0

9

0

9

1

6

5

8

7

9

8

7

4

3

8

7

0

9

8

7

8

7

6

5

2

1

6

5

4

3

4

3

2

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

(0

0

1

3

3

3

3

1

1

1

0

0

0

3

3

3

3

2

2

2

1

1

1

1

1

1

1

1

1

1

1

1

0

0

0

0

0

0

0

0

0

P a tie n t ID
P o s t-T r a in in g k n o w le d g e s c o r e

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

)

N u rs e (n = 1 0 )

2

8

8

8

7

7

8

7

7

4

4

1

8

8

7

7

7

7

7

8

8

7

7

2

2

2

2

0

0

0

0

4

4

3

3

3

3

1

1

1

T r a in in g k n o w le d g e s c o r e

V M W (n = 2 8 )

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

1

1

1

0

0

0

0

0

0

0

0

0

30

0

0

0

0

0

0

0

0

0

0

0

0

0

0
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V

Knowledge Score Assessment Among 1st group only
M id w ife (n = 2 )

20

10

0
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Willingness to Prescribe PQ for P.v

VII (Willingness and Acceptance)
Q: Are you willing to test patients for G6PD deficiency every time they have

malaria?
 Yes

 No

 I do NOT know

Pre
33%
Unsure

56%

No

11%

Yes
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Q: How willing are you to give Primaquine to a patient with P. vivax malaria and
normal G6PD test?
Not willing
1

2

3

4

5

6

Willing
7

 I don’t know

PRE-POST TRAINING
Post

2

3

34

14

3

0
4

7

1

1

0

0

0

0

2

0

1

0

0

50

76

Pre

Post
Pre

5

6

7

Q: How willing are you to give Primaquine single dose treatment for P.
falciparum for a patient NOT screened for G6PD deficiency?
Not willing

Willing

1

2

3

4

5

6

 I don’t know

Chart Title
80

Pre

Post

60
40
20
0
0

1

2

3

4

5

6

7

7
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Appendix Figure 1: Variables

Independent Variables

Dependent Variables

Attitutes towards malaria and PQ use
(perception of threat, susceptibility,
seriousness)

and control

Knowledge about Malaria (cause,
symptoms, transmission, treatment,
prevention), RDT testing and PQ

Practices related to Malaria prevention

Demographic characteristics(gender, age,
education level)
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Appendix Figure 2: G6PD color changes

